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Background
Fluorouracil (5-FU)-based chemotherapy is the
backbone of treatment for metastatic colorectal
cancer (mCRC). Oxaliplatin and irinotecan, as well
as the targeted agents bevacizumab and cetux-
imab, combined with 5-FU/leucovorin (LV) fur-
ther improve overall survival (OS) of mCRC from
12 months to more than 30 months in selected
patients. This article focuses on the evolution of
chemotherapy and targeted therapy in mCRC in
Taiwan. Studies with oral fluoropyrimidines are
beyond the scopes of this brief review.
Era of 5-FU/LV Infusion
Prior to 1990, 5-FU/LV was the only active drug
available to treat CRC. In 1997, Yeh et al re-
ported the outcomes of first- and second-line
chemotherapy with 24-hour infusion of high-
dose 5-FU/LV (HDFL) in 42 mCRC patients.1
The weekly HDFL regimen consisted of 5-FU
(2600 mg/m2/week) and LV (300 mg/m2/week)
administered over a 24-hour period. Of these 
42 patients, 29 (69%) had previous exposure to
lower-dose 5-FU. The overall response rate (RR)
was 42.9% [95% confidence interval (CI): 28–
59%]. The RR in patients with and without pre-
vious low-dose 5-FU exposure was 34.5% (10/29
patients; 95% CI: 17–54%) and 61.5% (8/13 pa-
tients; 95% CI: 31–86%), respectively. There was
no National Cancer Institute Common Toxicity
Criteria report of grade 3/4 hematological toxic-
ity. The median OS of the entire study group was
10 months.
Yang et al have reported on the same infusional
regimen in 36 mCRC patients who were either
chemotherapy-naïve or previously exposed to 
5-FU.2 The overall RR was 47.2% (95% CI: 30.1–
64.4%). Chemotherapy-naïve patients had a RR of
53.3% (95% CI: 24.7–81.9%), whereas previously
treated patients had only a RR of 42.9% (95% CI:
19.8–65.9%). The time to progression (TTP) and
median OS were 7.1 months and 11.9 months,
respectively. Hematological toxicity was < 6%
grade 1/2 and no grade 3/4. Both of these studies
have concluded that there is a better therapeutic
index for infusional 5-FU/LV compared with
bolus 5-FU/LV.
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Era of Oxaliplatin and Irinotecan
Emergence
In 2000, oxaliplatin and irinotecan were devel-
oped and further improved OS of patients with
mCRC. Sixty 5-FU-refractory mCRC patients un-
derwent a modified FOLFOX6 regimen: a 2-hour
oxaliplatin (80 mg/m2) infusion on day 1, fol-
lowed by a bolus injection of 5-FU (400 mg/m2);
and a 48-hour infusion of 5-FU (3000 mg/m2) and
LV (150 mg/m2) concurrently every 2 weeks.3 The
RR was 33.3%. Median progression-free survival
and OS were 4.8 and 12.1 months, respectively.
Notably, 20% of treated patients experienced 
severe adverse events, including grade 3/4 periph-
eral neuropathy, vomiting, and stomatitis. Subse-
quently, Yang et al have evaluated oxaliplatin with
either infusional or bolus 5-FU/LV in mCRC pa-
tients. Forty-eight chemotherapy-naïve patients
were reported in the infusional study with an over-
all RR of 41.7% and TTP of 10 months. In the
bolus study, in which patients failed 5-FU previ-
ously, the RR and TTP were 20.5% and 5 months,
respectively.4 Toxicity profiles were similar in both
studies; however, grade 3/4 peripheral neuropa-
thy was more frequently observed in the bolus
study, with 12.8% and 6.3% in the bolus and 
infusional studies, respectively.
Tai et al have evaluated the efficacy of the 
5-FU/LV/irinotecan (FOLFIRI) regimen in patients
who failed oxaliplatin/5-FU/LV treatment.5 The
regimen consisted of a 90-minute infusion of
irinotecan (180 mg/m2) and a 2-hour infusion
of LV (200 mg/m2), followed by a bolus injection
of 5-FU (400 mg/m2) and a 22-hour infusion of
5-FU (600 mg/m2) on the first 2 days of every 
2-week cycle. The RR was 22%, and the median
duration of response was 8 months. Grade 3/4
toxicities were acceptably low: neutropenia (7.7%)
and diarrhea (8.3%).
Although OS was not significantly different
between the sequences of the two chemotherapy
regimens, the FOLFIRI regimen as second-line
treatment followed by oxaliplatin/5-FU/LV or
HDFL6 demonstrated a poorer RR than oxaliplatin/
5-FU/LV followed by the FOLFIRI regimen. Yeh et al
have suggested downregulation of thymidylate
synthase expression and its mRNA by oxaliplatin
combined with 5-FU/LV as an explanation for
the better response observed with oxaliplatin/
5-FU/LV after irinotecan/5-FU/LV as second-line
treatment.6
Era of Targeted and Personalized Therapy
The development of targeted therapy promises
new advances in cancer treatment. Pivotal studies
of bevacizumab combined with standard chemo-
therapy as compared with chemotherapy alone
have demonstrated prolonged OS in mCRC pa-
tients in first- and second-line treatment of 4.7
(hazard ratio: 0.66, p<0.001) and 2.1 (hazard ratio:
0.75, p=0.011) months, respectively. Additionally,
either FOLFOX or FOFIRI combined with cetux-
imab, as compared with chemotherapy alone, both
revealed statistically significant improvement of
progression-free survival around 0.5–1.2 months
in KRAS wild-type mCRC patients.7 In Taiwan,
Yen et al have shown that a KRAS mutation, which
correlates with poor responsiveness to cetuximab
treatment, can be detected from blood samples.8
Wang et al have demonstrated that KRAS muta-
tion is an independent predictor of cetuximab
non-responsiveness in mCRC patients.
In 2010, innovative studies of bevacizumab 
or cetuximab were reported continuously at the
American Society Clinical Oncology (ASCO) meet-
ing. Post-progression addition of bevacizumab
into the next therapy regimen in mCRC showed
a benefit on median survival. Another study con-
cerning the sequence of regimens with FOLFIRI/
bevacizumab followed by cetuximab/irinotecan
in unselected mCRC patients revealed promising
TTP of FOLFIRI/bevacizumab (6 months) and OS
(not reached) after 25 months follow-up.
Advances in human genome analysis have
made possible personalized therapy in cancer.
UDP-glucuronosyltransferase 1A1 (UGT1A1) poly-
morphism predicts irinotecan toxicity. SN-38, a
metabolite of irinotecan, has been associated with
severe diarrheal episodes induced by irinotecan,
Y.L. Lin, et al
2 J Formos Med Assoc | 2011 • Vol 110 • No 1
Treatment of colorectal cancer in Taiwan
J Formos Med Assoc | 2011 • Vol 110 • No 1 3
and is inactivated by UGT1A1 isoforms. Yeh 
et al have reported that the frequency of the
UGT1A1*28 polymorphisms of homozygous
[(TA)7TAA/(TA)7TAA] genotype, which is related
to decreased UGT1A1 activity, was about 7.7% in
Taiwanese mCRC patients. This information could
be utilized to avoid the toxicity of irinotecan-based
therapy.9 High expression of ERCC1 (excision re-
pair cross-complementing 1) predicts unrespon-
siveness of oxaliplatin in mCRC treatment. Wang
et al have demonstrated that increased expres-
sion of ERCC1 protein is associated with low re-
sponse to FOLFOX-4 chemotherapy in Taiwan.10
Treatment of mCRC in Taiwan continues to
evolve. As research into personalized therapy
continues, literature review and data collection/
interpretation remain key elements in the progress
towards improved personalization of treatment.
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